Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Revascularization Timing in Acute Coronary Syndrome

Multivessel disease is often present in ST elevation acute myocardial infarction (STEMI) patients. The AHA/ACC 2021 revascularization guidelines recommend staged complete revascularization as class I, single-setting complete revascularization as class 2b, and recommend against culprit only revascularization.

Nueva y discrepante información sobre los vasos no culpables en el infarto

At present, we have more randomized studies (BIOVASC, FIRE and MULTISTAR) comparing staged vs single-setting complete revascularization, but we lack information to decide on the best strategy. 

This was a meta-analysis of 16 randomized studies including 11,876 STEMI and NSTEMI patients undergoing culprit only, single-setting, and staged complete revascularization, excluding those with cardiogenic shock. 

Primary end point was cardiovascular death or AMI.

3,056 patients received single-setting complete revascularization (25.7%), 4,328 patients received staged complete revascularization (36.4%) and 4,492 patients received culprit-only revascularization (37.8%). Mean age was 65 and they were mostly men. 

Primary end point resulted in favor of single-setting complete revascularization (odds ratio [OR], 0.52 [95% CI, 0.41–0.65]; OR, 0.74 [95% CI, 0.62–0.88] for staged complete and culprit only revascularization respectively), making this one the strategy of choice, followed by complete staged and finally culprit only. 

Read also: ULTIMATE III: Use of IVUS for Coronary De Novo Lesion Drug Coated Balloon Angioplasty.

Reduction in adverse events rate (MACE) also favored single-setting complete revascularization over the other two (OR, 0.42 [95% CI, 0.32–0.56]; OR, 0.62 [95% CI, 0.47–0.82] for complete staged and culprit only respectively), also all-cause mortality and AMI (OR, 0.52 [95% CI, 0.40–0.67]; OR, 0.78 [95% CI, 0.67–0.91]), AMI (OR, 0.39 [95% CI, 0.26–0.57]; OR, 0.73 [95% CI, 0.59–0.90]) and need for unplanned revascularization (OR, 0.30 [95% CI, 0.18–0.47]; OR, 0.46 [95% CI, 0.30–0.71]).

There were no differences in cardiovascular mortality between the strategies.

These results were consistent across STEMI, NSTEMI and unstable angina patients.

Conclusion

Single-setting complete revascularization might offer greater reduction of cardiovascular events rate in patients with acute myocardial infarction and multivessel disease. We need more, large scale, randomized studies comparing single-setting vs staged complete revascularization procedures to better assess the optimal timing for complete revascularization. 

 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Culprit-Only Revascularization, Single-Setting  Complete Revascularization, and Staged  Complete Revascularization in Acute Myocardial  Infarction: Insights From a Mixed Treatment  Comparison Meta-Analysis of Randomized Trials

Reference: Muhammad Haisum Maqsood, et al. Circ Cardiovasc Interv. 2024;17:e013737. DOI: 10.1161/CIRCINTERVENTIONS.123.013737.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...